Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback